113 139

Cited 1 times in

Clinical Utility of a New Automated Hepatitis C Virus Core Antigen Assay for Prediction of Treatment Response in Patients with Chronic Hepatitis C

 Mi Na Kim  ;  Hyon-Suk Kim  ;  Ja Kyung Kim  ;  Beom Kyung Kim  ;  Seung Up Kim  ;  Jun Yong Park  ;  Do Young Kim  ;  Sang Hoon Ahn  ;  Kwang-Hyub Han 
 Journal of Korean Medical Science, Vol.31(9) : 1431-1437, 2016 
Journal Title
 Journal of Korean Medical Science 
Issue Date
Antigens, Viral/blood* ; Antiviral Agents/therapeutic use ; Automation ; Drug Therapy, Combination ; Female ; Genotype ; Hepacivirus/genetics* ; Hepacivirus/isolation & purification ; Hepacivirus/metabolism ; Hepatitis C, Chronic/drug therapy ; Hepatitis C, Chronic/virology* ; Humans ; Immunoassay ; Interferon-alpha/therapeutic use ; Male ; Middle Aged ; Polyethylene Glycols/therapeutic use ; Polymerase Chain Reaction ; RNA, Viral/blood* ; Reagent Kits, Diagnostic ; Recombinant Proteins/therapeutic use ; Recurrence ; Ribavirin/therapeutic use ; Treatment Outcome
Chronic Hepatitis C ; HCV Core Antigen ; HCV RNA ; Treatment Response
Hepatitis C virus core antigen (HCV Ag) is a recently developed marker of hepatitis C virus (HCV) infection. We investigated the clinical utility of the new HCV Ag assay for prediction of treatment response in HCV infection. We analyzed serum from 92 patients with HCV infection who had been treated with pegylated interferon and ribavirin. HCV Ag levels were determined at baseline in all enrolled patients and at week 4 in 15 patients. Baseline HCV Ag levels showed good correlations with HCV RNA (r = 0.79, P < 0.001). Mean HCV Ag levels at baseline were significantly lower in patients with a sustained virologic response (SVR) than in those with a non SVR (relapse plus non responder) based on HCV RNA analysis (2.8 log₁?fmol/L vs. 3.27 log₁?fmol/L, P = 0.023). Monitoring of the viral kinetics by determination of HCV RNA and HCV Ag levels resulted in similarly shaped curves. Patients with undetectable HCV Ag levels at week 4 had a 92.3% probability of achieving SVR based on HCV RNA assay results. The HCV Ag assay may be used as a supplement for predicting treatment response in HCV infection, but not as an alternative to the HCV RNA assay.
Files in This Item:
T201604458.pdf Download
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Laboratory Medicine (진단검사의학교실) > 1. Journal Papers
Yonsei Authors
김도영(Kim, Do Young)
김범경(Kim, Beom Kyung) ORCID logo https://orcid.org/0000-0002-5363-2496
김승업(Kim, Seung Up) ORCID logo https://orcid.org/0000-0002-9658-8050
김자경(Kim, Ja Kyung) ORCID logo https://orcid.org/0000-0001-5025-6846
김현숙(Kim, Hyon Suk) ORCID logo https://orcid.org/0000-0001-5662-7740
박준용(Park, Jun Yong) ORCID logo https://orcid.org/0000-0001-6324-2224
안상훈(Ahn, Sang Hoon) ORCID logo https://orcid.org/0000-0002-3629-4624
한광협(Han, Kwang-Hyub) ORCID logo https://orcid.org/0000-0003-3960-6539
RIS (EndNote)
XLS (Excel)
사서에게 알리기


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.